Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

阿帕蒂尼 医学 临床终点 内科学 化疗 实体瘤疗效评价标准 肿瘤科 无进展生存期 临床研究阶段 外科 临床试验 胃肠病学
作者
Bo Zhang,Ling Qi,Xi Wang,Jianping Xu,Yun Liu,Lan Mu,Xingyuan Wang,Lidan Bai,Jing Huang
出处
期刊:Cancer communications [Wiley]
卷期号:40 (12): 711-720 被引量:104
标识
DOI:10.1002/cac2.12119
摘要

Abstract Background Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti‐angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects. Therefore, we aimed to investigate the efficacy and safety of camrelizumab plus apatinib combined with chemotherapy as the first‐line treatment of advanced ESCC. Methods In this single‐arm prospective phase II trial, patients with unresectable locally advanced or recurrent/metastatic ESCC received camrelizumab 200 mg, liposomal paclitaxel 150 mg/m 2 , and nedaplatin 50 mg/m 2 on day 1, and apatinib 250 mg on days 1‐14. The treatments were repeated every 14 days for up to 9 cycles, followed by maintenance therapy with camrelizumab and apatinib. The primary endpoint was objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Secondary endpoints included disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and safety. Results We enrolled 30 patients between August 7, 2018 and February 23, 2019. The median follow‐up was 24.98 months (95% confidence interval [CI]: 23.05‐26.16 months). The centrally assessed ORR was 80.0% (95% CI: 61.4%‐92.3%), with a median duration of response of 9.77 months (range: 1.54 to 24.82+ months). The DCR reached 96.7% (95% CI: 82.8%‐99.9%). The median PFS was 6.85 months (95% CI: 4.46‐14.20 months), and the median OS was 19.43 months (95% CI: 9.93 months – not reached). The most common grade 3‐4 treatment‐related adverse events (AEs) were leukopenia (83.3%), neutropenia (60.0%), and increased aspartate aminotransferase level (26.7%). Treatment‐related serious AEs included febrile neutropenia, leukopenia, and anorexia in one patient (3.3%), and single cases of increased blood bilirubin level (3.3%) and toxic epidermal necrolysis (3.3%). No treatment‐related deaths occurred. Conclusions Camrelizumab plus apatinib combined with liposomal paclitaxel and nedaplatin as first‐line treatment demonstrated feasible anti‐tumor activity and manageable safety in patients with advanced ESCC. Randomized trials to evaluate this new combination strategy are warranted. Trial registration This trial was registered on July 27, 2018, at ClinicalTrials.gov (identifier: NCT03603756).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
weinian完成签到,获得积分10
刚刚
刚刚
刚刚
小龙完成签到,获得积分10
1秒前
wqerdsfas发布了新的文献求助10
2秒前
高兴绿柳完成签到 ,获得积分10
3秒前
abcde的应助被whx采纳,获得20
4秒前
yt完成签到,获得积分10
4秒前
ARNAMO完成签到,获得积分10
4秒前
论文小能手完成签到 ,获得积分10
4秒前
Hello的应助被xw采纳,获得10
5秒前
Alice完成签到,获得积分10
5秒前
rzxk关注了科研通微信公众号
5秒前
闪闪机器猫发布了新的文献求助100
6秒前
6秒前
河里蹿发布了新的文献求助10
6秒前
6秒前
husuhew完成签到,获得积分10
7秒前
西西发布了新的文献求助10
7秒前
ggggbaby发布了新的文献求助10
7秒前
edme完成签到,获得积分20
8秒前
汉堡包的应助被xueee采纳,获得10
8秒前
8秒前
积极向上完成签到,获得积分10
9秒前
9秒前
9秒前
wqerdsfas完成签到,获得积分10
9秒前
9秒前
墨倾池完成签到,获得积分10
10秒前
11秒前
11秒前
11秒前
12秒前
受伤易巧发布了新的文献求助10
12秒前
咖喱完成签到,获得积分10
13秒前
dd完成签到,获得积分10
13秒前
14秒前
Lunyx完成签到,获得积分20
14秒前
shiqiyuan发布了新的文献求助10
14秒前
霸气的小天鹅完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153492
求助须知:如何正确求助?哪些是违规求助? 9550166
关于积分的说明 21696892
捐赠科研通 7742051
什么是DOI,文献DOI怎么找? 3425502
关于科研通互助平台的介绍 2550620
邀请新用户注册赠送积分活动 2469156